These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 21149605)

  • 1. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
    Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
    J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
    Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
    Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
    Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs.
    Gnjatic S; Atanackovic D; Matsuo M; Jäger E; Lee SY; Valmori D; Chen YT; Ritter G; Knuth A; Old LJ
    J Immunol; 2003 Feb; 170(3):1191-6. PubMed ID: 12538675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.
    Kreiter S; Selmi A; Diken M; Sebastian M; Osterloh P; Schild H; Huber C; Türeci O; Sahin U
    J Immunol; 2008 Jan; 180(1):309-18. PubMed ID: 18097032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
    J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
    Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
    Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.
    Lahoud MH; Ahmet F; Kitsoulis S; Wan SS; Vremec D; Lee CN; Phipson B; Shi W; Smyth GK; Lew AM; Kato Y; Mueller SN; Davey GM; Heath WR; Shortman K; Caminschi I
    J Immunol; 2011 Jul; 187(2):842-50. PubMed ID: 21677141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.